Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Newly developed synbiotics and the chemotherapy-damaged gut|
|Citation:||Journal of Evidence-Based Complementary & Alternative Medicine, 2013; 18(3):198-208|
|Publisher:||Sage Publications, Inc|
|Hanru Wang, Susan E.P. Bastian and Gordon S. Howarth|
|Abstract:||Mucositis is a common side-effect of cancer chemotherapy and radiotherapy. Features of mucositis include erythema, ulceration, and inflammation of the gastrointestinal tract accompanied by clinical symptoms of abdominal pain and digestive disturbances. New treatment strategies are required. Experimental evidence is accumulating showing therapeutic promise for new nutraceutical agents including probiotic bacteria, probiotic-derived factors, prebiotics, and plant extracts. However, the targeted development of new combinations of these agents (synbiotics) to combat mucositis remains largely unexplored. The current review addresses the potential for these nutraceutical agents to reduce the severity of chemotherapy-damaged mucositis by strategically aligning their underlying mechanism of action with features of mucositis pathogenesis. The potential for certain plant extracts to act as prebiotics, in combination with probiotics or their derived factors, is further investigated. These unique synbiotic formulations could form the basis of a new naturally sourced adjunctive approach to cancer chemotherapy.|
|Keywords:||Mucositis; probiotics; probiotic-derived factors; plant extracts; chemotherapy; cancer|
|Rights:||© The Author(s) 2013|
|Appears in Collections:||Animal and Veterinary Sciences publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.